Achieve reliable procedural success with the VBX Stent Graft.⁠

The VBX Stent Graft has been proven across years of study in a comprehensive clinical development program, in hundreds of bEVAR and fEVAR procedures both in the Gore EMBRACE and EXPAND Registries.b,c,1-3
people-group-black

371

patients

hospital-black

Across 29

centers

Study designs

The EMBRACE study was a multicenter, single-arm retrospective and prospective Registry, conducted to confirm the clinical performance and safety of the VBX Stent Graft for fEVAR and bEVAR in the treatment of aortic aneurysms involving the renal-mesenteric arteries.1,2

The EXPAND study was a post-market registry, evaluating the safety and performance data of the VBX Stent Graft for fEVAR and bEVAR in peripheral vessels in patients who require interventional treatment.1,3

EMBRACE Registry
(1-year outcomes)
(n=259)  
EXPAND Registry
(3-year outcomes)
(n=112)
Target vessel technical success1
Target vessel technical success1
bEVAR 99.6%
bEVAR 100%
fEVAR 100%
fEVAR 100%
Primary patency1
Primary patency1,4
bEVAR 98.9% 
bEVAR 93.6%
fEVAR 99.4% 
fEVAR 96.5%
Freedom from target vessel instability1
Freedom from target vessel instability1,4 
bEVAR 94.5%
bEVAR 94.5%
fEVAR 96.6% 
fEVAR 96.5% 

The VBX Stent Graft is stable and durable, made for repairs that last.⁠1,4

Male surgeon in scrubs with a surgical mask pulled down, smiling with arms crossed, surrounded by a pink glow.
Physicians trust the VBX Stent Graft – do you?

With over 20 years of clinical experience, Gore is a proven leader in stent graft technology.

 

Find out more
Image of an advertorial on real-world data of the VBX Stent Graft, which was published by Vascular News in Issue 110, which was published in April 2026.
What can real-world data tell us?

Explore clinical experience and registry findings for the VBX Stent Graft in fEVAR and bEVAR.c

 

Read the article

a. Procedural outcomes based on usage of legacy GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (BXA catalogue numbers).
b. The EMBRACE Registry enrolled 259 patients. The EXPAND Registry enrolled 112 patients in the fEVAR and bEVAR cohorts.1,2
c. The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (Reduced Profile, "BXB-"catalogue numbers) is indicated for use as a bridging stent graft to maintain visceral artery perfusion in the European Union. For other countries, see Instructions for Use for approved indications.

  1. Data on File 2025; W. L. Gore & Associates, Inc; Flagstaff. 
  2. W. L. Gore & Associates. Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent with Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries (EMBRACE). VBX 21-04. Published March 23, 2022. Updated January 1, 2025. Accessed July 26, 2025. https://clinicaltrials.gov/study/NCT05143138
  3. W. L. Gore & Associates. Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels (EXPAND). VBX 17-04. Published December 18, 2018. Updated February 16, 2024. Accessed July 26, 2025. https://clinicaltrials.gov/study/NCT03720704
  4. Usai MV, Gargiulo M, Haulon S, et al. A three-year experience with the balloon expandable GORE VIABAHN VBX in the treatment of thoraco-abdominal aortic aneurysms within the EXPAND trial. Journal of Vascular Surgery 2025;81(2):319–323.
IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

Product may not be available in all countries. Please check with your Gore representative for availability.
25PL2235-EN03 MAT-0113-1